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Abstract
The advent of high-throughput SNP genotyping methods has
advanced research into the genetics of common complex genetic
diseases such as ankylosing spondylitis (AS) rapidly in recent
times. The identification of associations with the genes IL23R and
ERAP1 have been robustly replicated, and advances have been
made in studies of the major histocompatibility complex genetics of
AS, and of KIR gene variants and the disease. The findings are
already being translated into increased understanding of the
immunological pathways involved in AS, and raising novel potential
therapies. The current studies in AS remain underpowered, and no
full genomewide association study has yet been reported in AS;
such studies are likely to add to the significant advances that have
already been made.
Introduction
Genetic factors are the primary determinants not only of the
risk of developing ankylosing spondylitis (AS) but also of its
severity [1], as assessed by radiographic measures or by self-
administered questionnaires such as the widely used Bath
Ankylosing Spondylitis Disease Activity Index and Bath
Ankylosing Spondylitis Functional Index [2,3]. The disease
has long been known to be highly familial, with siblings of a
case with the disease having >50 times risk of developing the
condition themselves compared with individuals in the
general population [4].
The main disease-causative gene in AS, HLA-B27, was the
first gene identified to be associated with any common
human arthropathy, and the discovery proved that the
familiality of the condition was, to a significant degree,
genetically determined. The disease is strongly associated
with the gene HLA-B27; however, only 1 to 5% of B27-
positive individuals develop AS, and there is increasing
evidence to suggest that other genes must also be involved.
B27-positive relatives of AS patients have a recurrence risk of
the disease 5.6 to 16 times greater than B27-positive
individuals in the general population, implying the presence of
non-B27 shared familial risk factors [5,6]. A major non-B27
contribution to susceptibility to AS is suggested by the
greater concordance rate of monozygotic twins (63%) than of
B27-positive dizygotic twin pairs (23%) [7].
Recurrence risk modeling indicates that the observed pattern
of disease recurrence in families best fits an oligogenic
disease model [8]. Extensive efforts to identify genes by
linkage mapping in families has proven relatively unproduc-
tive, with linkage demonstrated at genomewide significant
levels to only one region (chromosome 16q (LOD score 4.7))
[9]. No genomewide association study in AS has yet been
reported, although a screen of 14,500 common nonsynony-
mous SNPs has been reported, identifying the association of
the genes ERAP1 (formerly known as ARTS-1) and IL23R
with AS [10]. Through the use of high-throughput microarray-
based SNP genotyping techniques in adequately sized
cohorts, researchers are making rapid progress in identifying
genes in a wide variety of common human diseases, and it is
likely that this approach will be similarly successful in AS.
Major histocompatibility complex and
ankylosing spondylitis – progress beyond B27
Whilst HLA-B27 is clearly the primary AS-associated major
histocompatibility complex (MHC) gene, studies of HLA-B
subtypes, of other HLA-B alleles, and of MHC haplotypes
indicate that there are very probably other HLA-B and non-
HLA-B MHC genes important in the risk of developing AS.
HLA-B and HLA-B27 subtypes
The study of HLA-B27 subtypes has accelerated over the
past 5 years through improved DNA-based genotyping
methods. The Anthony Nolan Trust database (http://
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hla.alleles.org/class1.html) now reports 46 B27 subtypes,
making B27 one of the more polymorphic of HLA-B alleles.
The significance of the B27-subtype studies is that they
provide important information helpful in research into the
mechanism by which B27 causes AS. The fact that B27
subtypes exist on very different MHC haplotypes makes the
chance of a B27-linked gene being primarily responsible for the
association of B27 with AS much less likely. The sequence
differences between disease-associated subtypes point to
regions of B27 that are less important in causing susceptibility
to AS, whereas sequence differences in subtypes that are
differentially associated with AS are likely to be in regions
critical to the mechanism by which B27 increases the risk of
AS. For most subtypes too few carriers have been identified to
determine whether they are disease-associated. For some
subtypes, however there is evidence of differential strength of
association with AS. AS has been reported to occur with the
following subtypes: B*2701, B*2702 [11], B*2703 [12],
B*2704 [13], B*2705 [11], B*2706 [14], B*2707 [15],
B*2708 [15], B*2709 [16], B*2710 [17], B*2714 [18],
B*2715 [18], B*2719 [19] and B*2730 [20].
The recent report of cases of AS occurring in individuals
carrying the B*2709 subtype has raised the question of
whether this subtype is protective against AS, or is simply
less strongly associated with the disease. No case of AS had
been reported with B*2709 until these reports, suggesting
that this subtype is protective for AS [21]. Three cases have
now been reported with axial AS in B*2709 carriers. One
woman with ulcerative colitis and pre-radiographic AS has
been reported. This lady may have developed AS as a
consequence of other susceptibility factors related to
ulcerative colitis, such as genetic variation in IL23R, and her
HLA-B*2709 carriage may not have been involved in her
developing AS [22]. In a second AS case reported from
Sardinia carrying B*2709, the other HLA-B allele was
B*1403, potentially explaining the development of AS [23].
B*1403 has also been reported to possibly be associated
with AS [24,25]. This subtype has similar sequence to B27
around the B pocket of the peptide binding grove, carrying a
cysteine residue at position 67. This residue is thought to be
involved in B27-homodimer formation, potentially explaining
the association of these alleles with AS. A third case has
been reported from Tunisia, although no clinical details or
other genetic information were available [16]. These cases
confirm that whilst B*2709 has a weaker association with
disease in comparison with B*2705, it is not absolutely
protective for AS
The B*2706 subtype similarly has been shown to be less
strongly associated with AS than B*2704 in South-East Asia
[13]. As with B*2709, however, cases of AS have been
reported in B*2706 carriers, confirming that this subtype is
also not protective against AS but rather has a weaker
strength of disease association [26]. This is consistent with
previous family studies that demonstrate B*2704/*2706
compound heterozygotes can still develop AS [27]. The
Taiwanese study and others have also suggested that
B*2704 may be more strongly associated with AS than
B*2705.
These studies suggest that there is a hierarchy of strength of
association of B27 with AS, with B*2704 equally or more
strongly associated than B*2705, B*2702 and probably
B*2707, which are more strongly associated than either
B*2706 or B*2709. The author also thinks it is likely that
B*2703 is less strongly associated with disease than
B*2705, but sufficient data in African Americans do not yet
exist to make this conclusion firm. None of the other subtypes
are sufficiently common for any comment to be made about
their relative strength of association with AS. Most studies to
date reporting subtype frequencies have been quite limited,
with fewer than 200 AS cases reported. Much larger studies
of different ethnic group should be encouraged in order to
clarify the level of association of less frequent B27 subtypes,
as this could be very informative with regard to the
mechanism of association of B27 with AS.
HLA-B27 is clearly not the only HLA-B allele associated with
AS. Association with HLA-B60 has been reported by many
groups in both B27-positive cases and B27-negative cases
[28-30]. The strength of association of HLA-B60 with AS is
much weaker than the association with B27, with an odds
ratio of 3.6 [29]. It is uncertain whether HLA-B60 is also
disease-causing itself, or is a marker of an MHC haplotype
bearing other disease-causing genes. This is also the case for
B*1403, for which the strength of evidence for its genetic
association is modest and not fully established.
Major histocompatibility genes other than HLA-B
There is strong evidence from studies of association of other
MHC class II and class III genes with AS for the existence of
other MHC-encoded AS susceptibility genes. Pinpointing the
specific genes involved is a challenging task, given that the
MHC is characterized both by extreme diversity of specific
loci, and by extreme and complex linkage disequilibrium
patterns that must be tightly controlled for to avoid confusing
findings due to linkage disequilibrium from true association.
Several small association studies have implicated other MHC
genes in AS, although the studies have been too small and
targeted to determine whether these are primary associations
or are due to linkage disequilibrium with other loci (reviewed
in [31]).
Studying MHC markers (SNPs and microsatellites) on HLA-
B27-DRB1 haplotypes, we recently showed convincing
evidence for the existence of non-B27 MHC genes in AS
carried on both B27-positive and B27-negative strands [32].
Comparing B27-matched case and control haplotypes,
strong association was observed with DRB1 irrespective of
whether the haplotype carried HLA-B27 (B27-positive strand,
P = 4 x 10–4; B27-negative strand, P = 5 x 10–8). The effect
size of these associations is substantial, with the attributable
risk from these haplotypes being 34%. This study, although
quite large, was not adequately powered to identify the
specific gene variants involved.
This evidence strongly suggests that further studies of the
MHC for AS-susceptibility genes other than B27 are likely to
be quite fruitful, although the sample sizes required to
differentiate linkage disequilibrium effects from true
association are substantial. A model example of how to
perform such studies comes from research in type 1 diabetes
MHC genetics, where convincing evidence that HLA-A and
HLA-B are associated with disease susceptibility has recently
been reported in a disease hitherto considered HLA class II
restricted [33]. To achieve this evidence, over 13,000
controls were studied using dense SNP maps, and the
analysis was controlled for linkage disequilibrium with known
diabetes HLA class II associations. By contrast, most studies
of AS have either been quite small, involving a few hundred
samples, or have had inadequate control for the HLA-B
associations of the disease (that is, B27, B60 and potentially
other HLA-B alleles). Whilst smaller studies may provide
tantalizingly suggestive evidence of specific MHC genes
associated with AS, and may actually be correct, the past
record of such studies in AS and other rheumatic diseases
such as RA indicates that these findings are rarely replicated.
Nonmajor histocompatibility complex genes
and ankylosing spondylitis
As discussed in the Introduction, twin and family studies have
long suggested the existence of non-MHC susceptibility
genes for AS. In 2007 a study of 14,500 nonsynonymous
SNPs (that is, single-base polymorphisms that change the
amino acid sequence of a protein) by the Wellcome Trust
Case Control Consortium and the Australo-Anglo-American
Spondyloarthritis Consortium made the first robust
identifications of non-MHC susceptibility genes in AS, with
the identification of the associations with ERAP1 and IL23R
[10]. This study of 1,000 AS cases and 1,500 healthy
controls was at the time the largest association study in AS.
Nonetheless it still only screened <15% of the human
genome, and was only powered to identify moderately large
genetic effects compared with the magnitude of genetic
associations that are typically found in common diseases.
The association of AS with IL23R has been replicated in a
Spanish population [34], in a Canadian population [35] and
in a further English study [36], but as yet no replication has
been reported in Asian populations. To date, no replication
study of ERAP1 (formerly known as ARTS1) has been
published in AS, although associations have been reported
with type 1 diabetes [37] and cervical cancer [38].
IL23R has been shown to have pleiotropic effects, also being
associated with inflammatory bowel disease [39,40] and
psoriasis [41]. The primary associated polymorphism in these
diseases is thought to be the nonsynonymous SNP,
rs11209026, although that has yet to be formally established.
No association of IL23R was seen with Crohn’s disease in a
Japanese study, and it was noted that rs11209026 was
nonpolymorphic in that population [42], potentially explaining
the lack of association of the gene with the disease in that
ethnic group.
This genetic finding has led to substantial research activity
into the involvement of the TH17 lymphocyte pathway in AS.
Hitherto TH17 had been studied in mouse models of multiple
sclerosis (experimental autoimmune encephalomyelitis) and
rheumatoid arthritis (collagen-induced arthritis), yet to date
there is little to no evidence for either disease that genetic
variation in TH17-related genes such as IL23R, STAT3 or
JAK2 influences disease susceptibility. This lack of evidence
highlights again the uncertain relevance of many mouse
disease models to the human conditions they may pheno-
typically resemble.
Research into the mechanism by which IL23R polymor-
phisms influence susceptibility to autoinflammatory diseases
is in its early days, and it is not yet clear which cell type is
mainly functionally affected by the IL23R polymorphisms.
IL23R is expressed on several immunological cell types in
addition to TH17 cells, including macrophages, microglia,
natural killer cells and natural killer T cells, and it is not yet
clear which cell type is primarily affected by the IL23R
disease-associated variant. The demonstration of increased
TH17 lymphocyte numbers [43] and serum IL-17 levels [44]
in AS is consistent with a direct role of TH17 lymphocytes in
AS, but formal proof that this is the critical functional cellular
subset is awaited. Nonetheless, inhibition of TH17 activity is
being investigated as a possible therapeutic approach for
autoimmune disease. Antibodies to the IL-12p40 subunit (the
shared IL-23/IL-12 subunit) have been successfully trialed in
psoriasis [45,46] and in Crohn’s disease [47], and trials with
anti-IL-17 antibodies are shortly to commence in AS.
As with IL23R, we have much yet to learn about the
association of ERAP1 with AS and its underlying mechanism.
ERAP1 may affect disease risk either through its function to
trim peptides prior to loading into nascent HLA class I
molecules, or alternatively through its role in cleaving pro-
inflammatory cytokine receptors from the cell wall, including
TNF receptor 1, IL-1 receptor 2 and IL-6 receptor. There is
clear in vivo evidence that ERAP1 is important in HLA-class-I-
mediated immunity, with ERAP1–/– mice being shown more
prone to infection with Toxoplasma gondii, a vacuolar parasite,
due to defective presentation of parasite antigen by the murine
HLA class I system to CD8 T cells [48]. The effect on cytokine
receptor cleavage has been debated and as yet there are no
in vivo data to support this function. The key next steps are to
determine the main associated variant(s) of ERAP1, and to
assess its expression in health and disease. ERAP1
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expression is strongly affected by cis-acting SNPs, and there
are also multiple splice variants of ERAP1 known; whether
AS-associated variants affect either of these properties is
unknown. Resolution of the structure of ERAP1 would also
probably be highly informative about its true function.
Many other regions and genes have been implicated in
candidate gene or linkage mapping studies, which will not be
reviewed in depth here. Of these, the strongest associated
region is the IL-1 complex on chromosome 2p. Association
with this region has been reported by several groups [49-55],
making it unlikely that this is a false positive finding –
although definitive statistical evidence establishing the
association cannot yet be said to have been achieved. The
primary associated gene remains unknown.
Where to next in ankylosing spondylitis
genetics?
Clearly the next major steps in defining the genes involved in
AS are the completion of genomewide scans for suscep-
tibility to the disease and for its clinical manifestations. Initial
scans for disease-susceptibility loci are well advanced, but
the record in other diseases indicates that further scans in
new cohorts both in the same and different ethnic groups are
likely to be further informative. That is, the first susceptibility
scans in AS should not be expected to be definitive. Most
scans nowadays aim for ~2,000 cases and controls, but as
can be seen from Figure 1 this only provides adequate power
for quite high odds ratios (additive odds ratios of >1.5 to 1.7
depending on the minor allele frequency). Such large genetic
effect sizes are infrequent in common human diseases.
Scans will also probably be fruitful when investigating
disease manifestations such as occurrence of uveitis,
although it is not yet known whether that is independently
heritable from AS. There is evidence of strong heritability
(>60%) for radiographic change in AS, age of disease onset,
and severity scores such as the Bath Ankylosing Spondylitis
Disease Activity Index and the Bath Ankylosing Spondylitis
Functional Index. These quantitative traits will require even
larger numbers of cases to study, since they will be
investigated as cohort studies rather than in a case–control
design, where the costs are generally lower because of the
use of previously genotyped historic controls. A further
difficulty will be that the measures available to characterize
disease manifestations, such as the radiographic scores,
have been designed with their intended use as outcome
measures in clinical trials, and it is readily apparent that,
despite their heritability, they do not accurately assess the
disease process in AS. For example, the radiographic
modified Stoke Ankylosing Spondylitis Spine Score provides
equal weighting to radiographic disease in the cervical and
lumbar spine, when there is major diversity amongst patients
in the extent to which these sites are affected. It is to be
hoped that future AS outcome measures will be developed
aiming to more closely assess the biological processes
involved in AS pathogenesis rather than the more limited
scope of utility for intervention studies.
In most human diseases it has been accepted by researchers
that international collaboration will be required to achieve the
requisite sample sizes and to not waste resources. The
Wellcome Trust Case Control Consortium/Australo-Anglo-
American Spondyloarthritis Consortium study has
encouraged collaboration by making all genotype data in
cases and controls publicly available to bona fide researchers
[10], an unprecedented gesture in AS research. This open
approach is designed to ensure that the greatest value is
made of the public resources expended in these studies and,
perhaps more importantly, of the DNA samples and clinical
information provided by our most important stakeholders, the
AS patient community.
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Figure 1
Sample size requirements for genomewide scans. Sample size
(number of cases, assuming equal number of controls) to achieve 80%
power at α = 5 x 10–7, assuming D′ = 0.8 and that the minor allele
frequency of the marker SNPs and disease-associated variants are
equal. MAF, minor allele frequency.
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